Sugi Predict

Sugi Predict / Compounds / SCHEMBL6877632

SCHEMBL6877632

SCHEMBL6877632

O=[C]c1ccc2c(c1)CCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.45
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ NPC1 O15118 10/20 0.41
▸ RAB9A P51151 10/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ POLB P06746 4/20 0.40
▸ GRM5 P41594 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.37
▸ DRD2 P14416 2/20 0.37
▸ DRD3 P35462 2/20 0.37
▸ PNMT P11086 1/20 0.37
▸ STS P08842 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851854 0.95 STS (0.41) ALDH1A1CA12CA1CA2CA7
SCHEMBL9432052 0.77 ALDH1A1 (0.41) ALDH1A1CA12CA1CA2CA7
SCHEMBL29618357 0.77 PNMT (0.60) ALDH1A1CA12CA1CA2CA7
SCHEMBL8222195 0.77 PNMT (0.60) ALDH1A1CA12CA1CA2CA7
Hydrochloric Acid SCHEMBL30894888 0.76 PNMT (0.58) ALDH1A1CA12CA1CA2CA7
SCHEMBL22872285 0.74 DRD2 (0.51) ALDH1A1CA12CA1CA2CA7
SCHEMBL28963642 0.74 DRD2 (0.33) DRD2DRD3
SCHEMBL3363261 0.73 PNMT (0.60) DRD2DRD3PNMT
SCHEMBL8669783 0.73 TSHR (0.40) ALDH1A1CA12CA1CA2CA7
SCHEMBL29741121 0.73 PNMT (0.60) DRD2DRD3PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6013662-A ANTITUMOR, ANTICARCINOGENIC AGENTS RHONE-POULENC RORER S.A. (FR) 2000-01-11 — — US claimed
US-20040087655-A1 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (DE) 2004-05-06 — — US disclosed
EP-1351922-A2 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-10-15 — — EP disclosed
WO-2002055480-A2 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE MAX PLANCK GESELLSCHAFT (DE) 2002-07-18 — — WO disclosed
US-6218406-B1 AS ANTITUMOR AND ANTILEUKEMIC AGENTS AVENTIS PHARMA S.A. (FR) 2001-04-17 — — US disclosed
US-6124465-A Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments RHONE-POULENC S.A. (FR) 2000-09-26 — — US disclosed
US-6013662-A ANTITUMOR, ANTICARCINOGENIC AGENTS RHONE-POULENC RORER S.A. (FR) 2000-01-11 — — US disclosed
US-5585485-A Cephalosporin intermediate products BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 1996-12-17 — — US disclosed
US-5484928-A 2-(2-aminothiazol-4-yl)-2-oxoacetic acid derivatives BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 1996-01-16 — — US disclosed
EP-0312844-B1 Cephalosporin intermediates, process for their preparation and their use BIOCHEMIE GMBH (AT) 1994-06-22 — — EP disclosed
US-5003073-A Process for producing cephalosporin antibiotics, and novel intermediates for use in such process and their production SANDOZ LTD. (CH) 1991-03-26 — — US disclosed
EP-0312844-A1 Cephalosporin intermediates, process for their preparation and their use BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 1989-04-26 — — EP disclosed
US-4767852-A New process for producing cephalosporin antibiotics, and novel intermediates for use in such process and their production BIOCHEMIE (AT) 1988-08-30 — — US disclosed
WO-1985004404-A1 CEPHALOSPORINS BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 1985-10-10 — — WO disclosed
EP-0156771-A2 Cephalosporins BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 1985-10-02 — — EP disclosed
US-4477448-A CONTAIN PYRAZOLE SUBSTITUENTS SANDOZ LTD. (CH) 1984-10-16 — — US disclosed
EP-0037380-B1 NEW PROCESS FOR THE PRODUCTION OF CEPHALOSPORIN ANTIBIOTICS, AND NOVEL INTERMEDIATES USED IN SUCH PROCESS AND THEIR PRODUCTION BIOCHEMIE Gesellschaft m.b.H. (AT) 1984-09-12 — — EP disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 — — US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 — — US disclosed
EP-0037380-A2 New process for the production of cephalosporin antibiotics, and novel intermediates used in such process and their production BIOCHEMIE Gesellschaft m.b.H. (AT) 1981-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087655-A1 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine CORO1C, CORO1A, AGER ALDH1A1 3951/4885CA12 2817/4885CA1 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.